| Long term results of a phase II trial examining obintuzumab combined with ibrutinib for first line treatment of chronic lymphocytic leukemia. |
Home / Resource Library / A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial